Ethical issues regarding study designs used in serotonin-antagonist drug development

Annals of Pharmacotherapy

Volumn 30, Issue 10, 1996, Pages 1182-1184

  Holdsworth, Mark T ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIZAPRIDE; ANTIEMETIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; CORTICOSTEROID; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON; SEROTONIN 3 ANTAGONIST; SEROTONIN ANTAGONIST; TROPISETRON;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG POTENTIATION; DRUG RESEARCH; EDITORIAL; ETHICS; EXTRAPYRAMIDAL SYNDROME; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMED CONSENT; METHODOLOGY; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

EID: 0029784395     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603001019     Document Type: Editorial

References (31)

1. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, et al. On the receiving end: patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-8.
2. Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 1983;25(suppl 1):1-7.
3. Roila F. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination. Oncology 1993;50:163-7.
4. Soukop M, McQuade B, Hunter E, Stewart A, Kaye S, Cassidy J, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 1992;49:295-304.
5. Eguchi K, Ohmatsu H, Karato A, Nakajima S, Arioka H, Nishio M, et al. A randomized cross-over study of granisetron + dexamethasone vs high-dose metoclopramide + dexamethasone in patients with high-dose CDDP contained chemotherapy (abstract). Proc Am Soc Clin Oncol 1993;12:431.
6. OPRR reports: Protection of human subjects. Code of Federal Regulations. Title 45 CFR Part 46, section 46.116.4. Department of Health and Human Services, National Institutes of Health, June 18, 1991.
7. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990;322:810-6.
8. Cupissol DR, Serrou B, Caubel M. The efficacy of granisetron as a prophylactic antiemetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 1990;26(suppl 1):S23-7.
9. Citron ML. Placebos and principles: a trial of Ondansetron. Ann Intern Med 1993;118:470-1.
10. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med 1994;331:394-8.
11. Grunberg SM, Akerley WL, Krailo MD, Johnson KB, Baker CR, Cariffe PA. Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. Cancer Invest 1986;4:379-85.
12. Bruera ED, Roca E, Cedano L, Chacon R, Estevez R. Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep 1983;67:381-3.
13. Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675-8.
14. Hainsworth J, Harvey W, Pendergrass K, Kasimis B, Oblon D, Monaghan G, et al. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 1991;9:721-8.
15. Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992;10:1969-75.
16. Ruff P, Paska W, Goedhals L, Pouillart P, Riviere A, Vorobiof D, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 1994;51:113-8.
17. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995;13:1242-8.
18. Roila F, Tonato M, Basurto C, Bracarda S, Sassi M, Lupattelli M, et al. Ondansetron. Eur J Cancer 1993;29A(suppl 1):S16-21.
19. Morrow GR, Hickok JT, Rosenthal SN. Progress in reducing nausea and emesis: comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Cancer 1995;76:343-57.
20. Perez EA, Gandara DR. The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis. Semin Oncol 1994;21(suppl 5):15-21.
21. 3 receptor antagonists. Support Care Cancer 1994;2: 286-92.
22. Peters WP, Rogers MC. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer. N Engl J Med 1994;330:473-7.
23. Bui NB, Marit G, Hoerni B. High-dose metoclopramide in cancer chemotherapy-induced nausea and vomiting. Cancer Treat Rep 1982;66: 2107-8.
24. Kris MG, Tyson LB, Gralla RJ, Clark RA, Allen JC, Reilly LK. Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med 1983;309:433-4.
25. Terrin BN, McWilliams NB, Maurer HM. Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy. J Pediatr 1984; 104:138-40.
26. Marshall G, Kerr S, Vowels M, O'Gorman-Hughes D, White L. Antiemetic therapy for chemotherapy-induced vomiting: metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone. J Pediatr 1989;115:156-60.
27. Kris MG, Gralla RJ, Clark RA, Tyson LB, Groshen S. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone: a double-blind, randomized trial. Cancer 1987;60: 2816-22.
28. Rath U, Upadhyaya BK, Arechavala E, Bockmann H, Dearnaley D, Droz JP, et al. Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology 1993;50:168-72.
29. Zbrozek AS, Cantor SB, Cardenas MP, Hill DP Jr. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 1994;51:1555-63.
30. Cunningham D, Gore M, Davidson N, Miocevich M, Manchanda M, Wells N. The real costs of emesis: an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer 1993;29A:303-6.
31. Italian Group for Antiemetic Research. Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Ann Oncol 1994;5:585-9.